SEC Tracker
Get the app
TLSI · XBRL financial data

TriSalus Life Sciences financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TLSI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers5,1935,721*6,4577,3647,3498,261*9,16711,21311,56613,205*8,89911,407
Cost of goods and services sold589582*9719121,0041,216*1,4951,8021,9061,762*1,2301,508
Gross profit4,6045,139*5,4866,4526,3457,045*7,6729,4119,66011,443*7,6699,899
Research and development9,3677,639*5,8574,6664,2192,959*3,2963,9235,1762,570*3,2163,137
General and administrative9,0256,014*4,6273,9564,7274,656*4,9715,6576,6594,171*5,4515,159
Operating income (loss)(18,477)(14,118)*(11,685)(8,174)(8,739)(7,580)*(7,329)(7,332)(9,014)(3,271)*(8,411)(9,813)
Interest income116244*929715857*74134170177*164457
Interest expense43*38771,1421,068*1,2091,4231,4601,452*1,4361,490
Other income (expense)(13)(323)*(153)(44)(13)(102)*(251)(40)(94)(71)*(76)90
Income tax expense (benefit)01*37(3)(1)*5(3)50*44
Net income (loss)(1,286)(35,509)*(13,219)(4,332)(2,399)(10,108)*(10,375)(8,288)(10,811)(9,753)*1,539(9,187)
Earnings per share, basic USD per share(0.13)—(0.60)(0.21)(0.12)(0.37)*(0.39)(0.27)(0.96)(0.21)*0.03(0.16)
Earnings per share, diluted USD per share(0.13)—(0.60)(0.21)(0.12)(0.37)*(0.39)(0.27)(0.96)(0.21)*0.03(0.16)
Weighted average shares, basic thousands of shares13,1737,847*23,32323,90426,50227,561*28,52732,89943,05846,849*51,54058,297
Weighted average shares, diluted thousands of shares13,1737,847*23,32323,90426,50227,561*28,52732,89943,05846,849*52,31458,297

Balance sheet

CSV

Fiscal quarters (TLSI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents21,38311,7773,97016,48111,2888,52513,00026,49022,68720,43956,55346,288
Accounts receivable3,0523,5544,2774,7064,9125,0875,4535,5715,0006,5585,2156,459
Inventory1,6292,5452,9133,4433,9994,0484,1623,8073,2763,0773,7784,205
Total current assets29,04120,86213,19127,94123,80820,66925,09638,08433,32832,24468,13859,744
Property and equipment, net1,8972,0911,9651,8301,818———————
Right-of-use asset1,2521,1791,1961,1231,4271,2101,1371,103890861830798
Total assets33,55425,72517,88932,43127,47723,97128,62541,31736,46335,33170,97962,448
Accrued liabilities6,60010,55611,4239,4077,8777,3558,4037,0786,7738,0967,0677,107
Total current liabilities9,30514,68714,39411,9979,91810,22811,7539,32410,91011,49911,78611,172
Long-term debt—0—21,28621,67822,08431,69932,27432,76433,04633,07933,065
Lease liability, non-current—1,156———1,311———1,186——
Total liabilities25,06751,66352,81256,58047,91149,86562,99560,74063,18869,19258,17255,898
Accumulated deficit(212,867)(248,377)(261,596)(265,928)(269,441)(279,549)(289,924)(298,212)(320,970)(330,583)(329,044)(338,231)
Total stockholders' equity8,487(25,938)(34,923)(24,149)(20,434)(25,894)(34,370)(19,423)(26,725)(33,861)12,8076,550
Total liabilities and equity33,55425,72517,88932,43127,47723,97128,62541,31736,46335,33170,97962,448
Common shares outstanding (cover page) thousands of shares26,31726,75827,15929,31130,49332,27237,83949,86749,96461,30661,41761,575

Cash flows

CSV

Fiscal quarters (TLSI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,286)(35,509)*(13,219)(4,332)(2,399)(10,108)*(10,375)(8,288)(10,811)(9,753)*1,539(9,187)
Stock-based compensation260*1,000*1,0861,275*1,383*1,697*1,6201,892*3,422*2,197*2,4722,616*
Net cash from operating activities(40,184)*(8,849)*(10,867)(13,422)*(10,847)*(5,707)*(4,499)(7,320)*(3,709)*(2,484)*(6,480)(10,129)*
Purchases of property and equipment178*372*6660*169*50*754(93)*216*41*14182*
Net cash from investing activities(9,542)*(700)*(66)(60)*(169)*(50)*(714)93*(176)*(41)*(141)(82)*
Proceeds from issuing common stock0*0*3,1413,602*5,843*2,951*022,211*0*(211)*42,6250*
Proceeds from issuing equity—————year only——————
Net cash from financing activities61,744*43*3,12625,993*5,823*2,994*9,68820,717*82*277*42,385(54)*
Net change in cash12,019*(9,506)*(7,807)12,511*(5,193)*(2,763)*4,47513,490*(3,803)*(2,248)*35,764(10,265)*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
TriSalus Life Sciences46,28811,407(10,129)*61.6M4.6 quarters 10-QJun 30, 2026
CVRx64,58615,705(8,826)*26.6M7.3 quarters 10-QJun 30, 2026
LENSAR13,56516,495(127)*12.3M106.8 quarters 10-QJun 30, 2026
KORU Medical Systems8,28812,045216*46.2M— 10-QJun 30, 2026
InfuSystem Holdings96436,9336,777*19.9M— 10-QJun 30, 2026
Pulmonx52,69022,835(3,183)*43.6M8.5 quarters 10-QSep 30, 2026
Neuronetics19,19741,568(1,008)*76.2M19.0 quarters 10-QJun 30, 2026
Microbot Medical3,152241(4,989)*67.2M13.5 quarters 10-QJun 30, 2026
Picard Medical382,954(1,352)*2.3M0.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.